samplefor sexual health
99%+ · 10mg · Lyophilized
Bulk discount
3+ pcs
€23.65
−5%
5+ pcs
€22.41
−10%
10+ pcs
€21.16
−15%
Discount is applied automatically at checkout.
🎉 One free — saved €24.9
Preview: offer goes live at launch.
The catalog is not yet accepting orders. Join the list.
In Stock - Ships within 24 hours
Free shipping over €49
This product is sold strictly for in lab conditions (in vitro) research purposes. Not approved for human consumption.
Verified above 98%
98%+ verified — most batches reach 99%+
Included
Independent analysis from accredited laboratories
EU Shipping
3-7 days across the EU (Bulgaria — 1-2 days)
Secure Payment
Cash on delivery
PT-141
Melanocortin Receptor Agonist | Sexual Dysfunction Treatment
In short
Melanocortin agonist with MC4R affinity studied in neuroendocrine models for central regulation of sexual function.
Best sellers
Education
Related resources
Ready-to-use starter kit
PT-141 (Bremelanotide) is a synthetic peptide engineered based on the naturally occurring alpha-MSH hormone. At the molecular level, it acts as an agonist of the melanocortin receptors (MC3R and MC4R) within the central nervous system. Scientists study it in animal models to observe its influence on neural pathways associated with sexual function. Although the active substance bremelanotide is an FDA and EMA-approved medication (Vyleesi®), the molecule offered here is strictly research-grade and is not a pharmaceutical drug.
Research reagent for laboratory use only. Not a medicine. For medical questions, consult a physician.
Scientific review
Written by
Калина Тодорова
Magister Pharmaciae, MSc Pharmacy
Reviewed by
Борис Маринов
MSc Biochemistry & Molecular Biology
Reviewed on
PT-141 (Bremelanotide) is an FDA-approved synthetic peptide that acts as a melanocortin receptor agonist, specifically targeting MC3R and MC4R receptors in the central nervous system. Unlike traditional ED medications that work through vascular mechanisms, PT-141 directly influences sexual arousal pathways in the brain, making it effective for both male and female sexual dysfunction.
Central MC4R agonist — only sexual agonist with FDA approval (Vyleesi 2019) Does not rely on nitrate-mediated vasodilation Effective even under hormone insufficiency ~2.7h half-life for on-demand dosing
Activates melanocortin receptors (MC3R/MC4R) in the central nervous system, triggering sexual arousal pathways independent of vascular mechanisms
FDA-approved for premenopausal women with acquired, generalized HSDD
Effective in men including those unresponsive to PDE5 inhibitors
Improves physiological and subjective arousal measures
Dosing
The typical regimens you'll see in the published research - for reference when planning in vitro or in vivo experiments. Not medical advice.
Disclaimer
These are regimens discussed in the research literature, not medical advice. Consult a healthcare provider before use.
Timing
45-60 minutes before anticipated sexual activity
[Calculator]
Change water and dose · results update in real time
from product
Visual indicator
Pull to mark 5.0
5.0marks
Standard insulin syringe 1 ml (100 marks)
Concentration
5.00mg/ml
Dose volume
0.050ml
U-100 units
5.0units
Doses per vial
40doses
Recommended needle
29G–30G / 1 ml insulin
Small volume — draw slowly; 30G works for finer precision
Cycle planner: vials for 12 weeks, cost, schedule
Opens full calculator
Results are reference values - for in vitro work. Verify against the published literature for the specific peptide.
[Step by step]
6 steps from a sealed vial to the injection. Plain language.
Peptide vial (10 mg), bacteriostatic water vial, 1 larger syringe (3-5 ml) for drawing water and 1 insulin (1 ml) for doses. Alcohol swabs for sanitizing the caps.
Wash your hands before starting.
Wipe the rubber cap of the water vial with an alcohol swab. Insert the needle, invert the vial and draw exactly 2 ml. Get the exact volume from the calculator.
Larger syringe = smaller error in volume.
Wipe the peptide vial cap. Tilt the vial 45° and release the water SLOWLY down the inner wall. Peptides are fragile — a direct stream onto the powder denatures them.
SLOWLY · DOWN THE WALL · NOT ONTO THE POWDER.
Hold the vial between both palms and swirl slowly. DO NOT shake or flip sharply — peptides break down under mechanical stress.
DON'T SHAKE. Like tea — not like a cocktail.
The powder should fully dissolve. The solution is clear, no visible particles. If cloudy or with sediment — discard (wrong water or bad batch).
Clear = OK. Cloudy = discard.
With the insulin syringe draw the exact marks from the calculator. Swab the skin (abdomen 5 cm around the navel, thigh, or buttock), pinch a fold, insert at 45-90° and inject slowly.
Rotate sites every injection to avoid lipohypertrophy.
Schedule
45-60 minutes before anticipated sexual activity
Allow vial to reach room temperature (15-20 minutes)
Clean vial top with alcohol swab and allow to dry
Calculate required bacteriostatic water volume using the calculator below
Draw calculated volume of bacteriostatic water into syringe
Inject water slowly down the inside wall of the vial (never directly onto powder)
Gently swirl until powder completely dissolves (never shake)
Solution should be clear - discard if cloudy or contains particles
Store reconstituted solution in refrigerator at 2-8°C
Nausea
common·Vyleesi label
Transient BP rise (5-10 mmHg)
common
Flushing
common
Headache
common
Injection-site reaction
common
Focal hyperpigmentation (rare, >8/month)
rare
Compatibility
The pairings below come from research literature and established biohacker stacking patterns. Click a card for the full reasoning - when the partner is in our catalog you'll see a direct order link too.
This is a literature overview, not medical advice. Pairs not listed are not proven safe - they simply lack enough published data.
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
FDA Approval Trial for Hypoactive Sexual Desire Disorder (2019)
Human | 1.75mg subcutaneous | As needed | 24.5% improvement vs 17.2% placebo
Phase 3 trials in premenopausal women with HSDD showed statistically significant improvements in sexual desire and reduced distress related to low sexual desire.
Male Erectile Dysfunction Clinical Trial (2017)
Human | 1-20mg intranasal | Single dose | Dose-dependent erectile response
Clinical studies demonstrated PT-141 induced erections in men with ED, including those unresponsive to PDE5 inhibitors, through central nervous system pathways.
Mechanism of Action Study (2016)
In vitro + Animal | Various doses | Receptor binding assays
Research confirmed PT-141 selectively binds MC3R and MC4R receptors, activating neural pathways involved in sexual arousal without peripheral vasodilation.
Female Sexual Arousal Disorder Trial (2013)
Human | 0.75-1.25mg subcutaneous | Single dose | Improved arousal metrics
Placebo-controlled study showed improvements in vaginal blood flow and subjective arousal measures in postmenopausal women with arousal disorder.
for longevity
No reviews yet. Be the first.
Share your experience with this peptide. We publish after a short moderation.
